scholarly journals Evolution of the Human Cytokine Response from Acute Illness to Disease Resolution in SARS-Cov-2 Infection—Implications for Therapeutic Monitoring and Therapeutic Targets

Author(s):  
George P. Drewett ◽  
Ana Copaescu ◽  
Effie Mouhtouris ◽  
Natalie Hannan ◽  
Fiona James ◽  
...  
2021 ◽  
Author(s):  
Yuki Yamamoto ◽  
Sabrina La Salvia ◽  
Sahoo Susmita ◽  
Hidetoshi Tahara

Non-coding RNAs are a species of RNA that are not translated to proteins. These include transfer RNAs and ribosomal RNAs, microRNAs, transfer RNA-derived fragments, and long non-coding RNA. It is known that expression levels of some non-coding RNAs included microRNAs are altered in cancer cells or tumor tissues. Moreover, expression profiles of such non-coding RNAs correlate between tissues and body fluids. Therefore, several non-coding RNAs are being used as diagnostic/prognosis biomarkers or therapeutic targets in cancer. In this chapter, we review about representative non-coding RNAs and introduce especially microRNA as diagnosis/prognosis biomarkers and therapeutic targets.


2006 ◽  
Vol 8 (1) ◽  
pp. 13-20 ◽  
Author(s):  
W J Jordan ◽  
J Eskdale ◽  
M Boniotto ◽  
M Rodia ◽  
D Kellner ◽  
...  

Science ◽  
1996 ◽  
Vol 274 (5293) ◽  
pp. 1739-1744 ◽  
Author(s):  
P. S. Moore ◽  
C. Boshoff ◽  
R. A. Weiss ◽  
Y. Chang

2005 ◽  
Vol 8 (2) ◽  
pp. 132-137 ◽  
Author(s):  
Danielle Posthuma ◽  
Ingrid Meulenbelt ◽  
Anton J.M. de Craen ◽  
Eco J.C. de Geus ◽  
P. Eline Slagboom ◽  
...  

2010 ◽  
Vol 28 (8) ◽  
pp. 871-879 ◽  
Author(s):  
Patrick Crocker ◽  
Omid Zad ◽  
Truman Milling ◽  
Todd Maxson ◽  
Benjamin King ◽  
...  

2005 ◽  
Vol 8 (2) ◽  
pp. 132-137 ◽  
Author(s):  
Danielle Posthuma ◽  
Ingrid Meulenbelt ◽  
Anton J. M. de Craen ◽  
Eco J. C. de Geus ◽  
P. Eline Slagboom ◽  
...  

AbstractThrough its ability to induce the enhanced release and production of cytokines, amyloid-β is responsible for the chronic inflammatory response that contributes to Alzheimer's disease (AD). Determining whether the response of monocytes to amyloid-β stimulation is under genetic control may help understand the basis of why some people are more prone to develop neuronal degeneration than others. In the current study we investigated the heritability of the cytokine (IL-10, IL-6, IL-1β, IL-1ra, TNF-[.alpha]) production capacity upon ex vivo stimulation with amyloid-β in whole blood samples of 222 twins and 85 singleton siblings from 139 extended twin families. It was found that individual differences in amyloid-β-induced cytokine production capacity are to a large extent of genetic origin, with heritability estimates ranging from 55% (IL-1β) to 68% (IL-6). We conclude that genes influencing amyloid-β-induced cytokine response may provide clues to the progression of AD pathology.


1998 ◽  
Vol 25 (2‐3) ◽  
pp. 83-265 ◽  
Author(s):  
J. L. Bidwell ◽  
N. A. P. Wood ◽  
H. R. Morse ◽  
O. O. Olomolaiye ◽  
G. J. Laundy

2012 ◽  
Vol 82 (4) ◽  
pp. 260-266 ◽  
Author(s):  
Salah E. Gariballa ◽  
Sarah J. Forster ◽  
Hilary J. Powers

Background: Although a number of studies have reported raised total plasma homocysteine (tHcy) concentrations in free-living older people, there are no data on homocysteine response to a mixed nutrient supplement in older patients. A raised plasma homocysteine concentration in older patients is partly a reflection of their co-morbidity, including impaired renal function, and there is uncertainty about the extent to which dietary interventions can improve plasma tHcy. Aim: To determine the plasma tHcy response to dietary supplements during acute illness. Methods: Two-hundred and thirty-six hospitalized, acutely ill older patients, who were part of a randomized double-blind placebo-controlled trial, were assigned to receive a daily oral nutritional supplement drink containing 1.3 mg of vitamin B2, 1.4 mg of vitamin B6, 1.5 μg of B12, 200 μg of folic acid, or a placebo, for 6 weeks. Outcome measures were plasma tHcy concentration at baseline, 6 weeks, and 6 months. Results: The mean plasma tHcy concentration fell among patients given the supplements (mean difference 4.1 µmol/L [95 % C.I, 0.14 to 8.03), p = 0.043], but tHcy concentration increased between 6 weeks and 6 months, after patients stopped taking the supplements [mean difference -2.0 µmol/L (95 % C.I, -03.9 to -0.18), p = 0.033]. About 46 % of patients in the placebo group and 55 % of patients in the supplement group had hyperhomocysteinemia (>14 µmol/L) at baseline compared with 45 % and 29 % at the end of the treatment period. Conclusions: A mixed nutrient supplement containing physiological amounts of B vitamins significantly reduced plasma tHcy concentrations in older patients recovering from acute illness.


Sign in / Sign up

Export Citation Format

Share Document